Investigator Initiated Research
Currently, our primary area of research interest is opioid overdose reversal. The FDA approval of Nalmefene HCl Injection has given healthcare professionals an additional treatment option for the management of known or suspected opioid overdose.
However, there is limited data on the use of Nalmefene HCl Injection in today’s opioid overdose environment. Outcomes associated with the use of Nalmefene HCl Injection are of particular interest.
Purdue Pharma L.P. typically funds investigator-initiated research (IIR) projects based on a competitive request for proposal (RFP) process. The current cycle has completed. Please check back at a later date for new funding opportunities.
Please note, however, that we will consider research proposals received outside the RFP cycle. Such proposals will also be evaluated by a medical and scientific review committee and will be subject to availability of research funds. If you have questions or would like to submit a research proposal, please contact firstname.lastname@example.org.
Important Information About Nalmefene HCl Injection
Nalmefene HCl Injection, a sterile solution containing 2 mg/2 mL (1 mg/mL) in vial form for intravenous, intramuscular, and subcutaneous injection, was FDA approved in February 2022.
Indications and Usage
Nalmefene HCl Injection is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids. Nalmefene HCl Injection is indicated in the management of known or suspected opioid overdose.
Nalmefene HCl Injection is contraindicated in patients with a known hypersensitivity to the product.
Warnings and Precautions
Nalmefene HCl Injection is associated with the following Warnings and Precautions: Use of Nalmefene in Emergencies, Risk of Recurrent Respiratory Depression, Cardiovascular Risks with Narcotic Antagonists, Risk of Precipitated Withdrawal, Incomplete Reversal of Buprenorphine, and Use in Pediatric Patients. Patients treated with Nalmefene HCl Injection should be observed until, in the opinion of the physician, there is no reasonable risk of recurrent respiratory depression.
The most common adverse reactions (>1%) reported in clinical trials with Nalmefene HCl Injection were nausea (18%), vomiting (9%), tachycardia (5%), hypertension (5%), postoperative pain (4%), fever (3%), and dizziness (3%).
Please consult the Nalmefene HCl Injection Full Prescribing Information found here for complete product information.
- Nalmefene HCl Injection [Full Prescribing Information]. Stamford, CT: Purdue Pharma L.P.